Related Experiment Video
Updated: Jul 13, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Bevacizumab demonstrates activity in advanced refractory fallopian tube carcinoma
1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine Medical Center, Orange, California, USA.
Abstract:
The targeting of angiogenesis pathways in the treatment of gynecological cancers is an exciting development in cancer therapy. Bevacizumab has been shown to have activity in ovarian cancer through its inhibition of the vascular endothelial growth factor. Fallopian tube carcinoma is a rare malignancy and is often treated in a similar manner as ovarian carcinoma. We present a case of a complete response in a woman with refractory metastatic fallopian tube carcinoma treated with bevacizumab. This report demonstrates the significance of anti-angiogenesis therapy in the treatment of these tumors.
Insights
Bevacizumab, an anti-angiogenesis drug, achieved a complete response in a patient with refractory metastatic fallopian tube cancer. This highlights the potential of targeting vascular endothelial growth factor in rare gynecological malignancies.
Area of Science:
- Oncology
- Gynecologic Oncology
- Cancer Therapeutics
Background:
- Angiogenesis pathways are crucial targets in gynecological cancer treatment.
- Bevacizumab inhibits vascular endothelial growth factor (VEGF), showing efficacy in ovarian cancer.
- Fallopian tube carcinoma, a rare malignancy, shares treatment similarities with ovarian cancer.
Observation:
- A case study of a patient with refractory metastatic fallopian tube carcinoma is presented.
- The patient was treated with bevacizumab, a VEGF inhibitor.
- A complete response was observed following the treatment.
Findings:
- Bevacizumab demonstrated significant activity in a patient with refractory metastatic fallopian tube carcinoma.
- Complete tumor regression was achieved, indicating potent anti-cancer effects.
- The study supports the efficacy of anti-angiogenesis therapy in this rare cancer.
Implications:
- Anti-angiogenesis therapy, specifically bevacizumab, holds promise for treating rare gynecological tumors.
- Targeting VEGF pathways can be a viable strategy for refractory metastatic fallopian tube carcinoma.
- This case underscores the importance of exploring novel therapeutic approaches in gynecologic oncology.
